⚠ Evidence warning: Clinical trials or other evidence do not support the claim that the Val/Ala result of the manganese superoxide dismutase gene is useful for personalizing antioxidant strategy. This page keeps it as a report of what people, websites or other media say.
Manganese for Antioxidant Defense (MnSOD/SOD2)
Manganese superoxide dismutase (MnSOD, also called SOD2) is often described as the most critical antioxidant enzyme in the body, largely on the evidence of mouse knockout studies. Located exclusively in the mitochondrial matrix where 90% of cellular reactive oxygen species are generated, MnSOD catalyzes the dismutation of superoxide radicals into hydrogen peroxide and oxygen — the first and most critical step in mitochondrial antioxidant defense. The enzyme's importance is most starkly demonstrated by genetic knockout: SOD2-null mice die within 1-3 weeks of birth from dilated cardiomyopathy, neurodegeneration, and metabolic acidosis. A common human variant (Val16Ala, also called rs4880) changes how efficiently MnSOD is imported into mitochondria — in laboratory tests the Val form is imported less efficiently than the Ala form — and has been studied for links to heart, kidney and nerve disease, cancer and aging, with mixed results; a 2008 meta-analysis found no overall link to cancer. Adequate manganese is the dietary input that keeps this critical defense system running.
Table of Contents
- Why MnSOD Is the Most Critical Antioxidant Enzyme
- The Dismutation Reaction: Superoxide to Hydrogen Peroxide
- SOD2 Knockout Mortality and the Indispensability Argument
- SOD2 Polymorphisms: Val16Ala (rs4880) and Disease Risk
- SIRT3 Regulation of MnSOD Activity (Acetylation Code)
- Oxidative Stress in Aging and the Mitochondrial Theory
- Disease Associations: Cancer, Neurodegeneration, Cardiomyopathy
- Assessing MnSOD Activity and Manganese Status
- Practical Interventions: Diet, Lifestyle, Drug Considerations
- Key Research Papers
- Connections
- Featured Videos
Why MnSOD Is the Most Critical Antioxidant Enzyme
The cell contains a layered antioxidant defense system. The first tier consists of three superoxide dismutases — SOD1 (CuZnSOD) in cytoplasm, SOD2 (MnSOD) in mitochondrial matrix, and SOD3 (extracellular CuZnSOD) in the extracellular space. The second tier consists of catalase (peroxisomes) and the glutathione peroxidase / glutathione reductase system. The third tier includes small-molecule antioxidants like ascorbate (vitamin C), alpha-tocopherol (vitamin E), glutathione, and ubiquinol (coenzyme Q10).
Of all these defenders, MnSOD has the strongest claim to being most critical for these reasons:
- Location — mitochondria generate the overwhelming majority (estimates range from 80–95%) of cellular reactive oxygen species. Electron leakage from complexes I and III of the electron transport chain produces superoxide directly into the mitochondrial matrix, and MnSOD is the only superoxide dismutase positioned to intercept it there.
- Substrate — superoxide is the parent reactive oxygen species. Most other reactive oxygen species (hydrogen peroxide, hydroxyl radical, peroxynitrite) are downstream products. Stopping the cascade at superoxide is more efficient than mopping up the downstream radicals afterward.
- Knockout phenotype — SOD2-null mice die within 1-3 weeks of birth. SOD1-null mice develop normally but have shorter lives, and in a 2005 study more than 70% of them developed liver nodules (nodular hyperplasia or liver cancer) later in life. SOD3-null mice are viable. The contrast — death within weeks versus a shortened life — is the main evidence for MnSOD's unique indispensability.
- Conservation — MnSOD is one of the most evolutionarily ancient enzymes in life, present in essentially all aerobic organisms from bacteria to humans, with the active-site manganese and overall protein fold conserved across two billion years.
This is why manganese, though needed only in trace amounts, is essential: MnSOD is the only superoxide dismutase inside the mitochondrial matrix. A 2018 review adds that superoxide dismutases have dual roles — limiting damage from reactive oxygen species and regulating the cell signals these molecules carry — and that all oxygen-using organisms have several of them, placed in different parts of the cell.
The Dismutation Reaction: Superoxide to Hydrogen Peroxide
The MnSOD-catalyzed reaction is a two-step dismutation in which two superoxide radicals are converted to one molecule of hydrogen peroxide and one molecule of molecular oxygen:
Step 1: Mn(III) + O2·− → Mn(II) + O2
Step 2: Mn(II) + O2·− + 2H+ → Mn(III) + H2O2
Net: 2 O2·− + 2H+ → H2O2 + O2
The reaction is very fast, close to the rate at which superoxide can reach the enzyme — one of the fastest known enzymatic reactions — although a 2001 kinetic study notes that human MnSOD's catalysis is limited at micromolar superoxide levels by a peroxide-inhibited complex with the manganese. This speed is necessary because superoxide, while a relatively mild radical itself, rapidly reacts with nitric oxide to produce peroxynitrite (an extremely damaging species) and with iron-sulfur clusters in enzymes like aconitase to inactivate them and release reactive iron.
The hydrogen peroxide product is then converted to water by glutathione peroxidase (using glutathione as electron donor) or by catalase in peroxisomes. If either downstream enzyme is impaired (low glutathione, low selenium, low catalase), hydrogen peroxide accumulates and can be converted via Fenton chemistry to hydroxyl radical, the most damaging reactive oxygen species. This is why MnSOD never functions in isolation — it is the entry point of an integrated relay.
Each MnSOD subunit contains one manganese ion at its active site, coordinated by three histidines, one aspartate, and one water molecule. The manganese cycles between Mn(III) and Mn(II) oxidation states during catalysis. The mature human MnSOD is a homotetramer (four identical subunits), with each subunit carrying one manganese ion, giving the assembled enzyme four active sites.
SOD2 Knockout Mortality and the Indispensability Argument
The most direct evidence for MnSOD's critical role comes from genetic knockout experiments in mice. The original SOD2-null mouse was reported by Li and colleagues in Nature Genetics in 1995, with two independent confirmations from other groups within a few years.
The phenotype is severe and rapid:
- Survival: days to weeks — in the 1995 line, homozygous mice died within the first 10 days of life; a second line (1996) survived up to 3 weeks
- Dilated cardiomyopathy — the heart, with its high mitochondrial density and continuous workload, is the first organ to fail. Histology shows myocyte vacuolization and contraction-band necrosis. (In the 1996 line only about 10% of the mice had markedly enlarged, dilated hearts.)
- Hepatic steatosis with mitochondrial damage — the liver shows fat accumulation and severely impaired mitochondrial respiration
- Metabolic acidosis — defective tricarboxylic acid (TCA, or Krebs) cycle function (because superoxide inactivates aconitase) blocks oxidative adenosine triphosphate (ATP) synthesis, forcing reliance on anaerobic glycolysis with lactate accumulation
- Neurodegeneration — the 1996 line showed degeneration of neurons in the basal ganglia and brainstem, with weakness, rapid fatigue and circling movements; spongiform degeneration of the brain cortex and brainstem appeared in mice kept alive longer with an SOD mimetic (1998)
- Antioxidant rescue — treatment with the manganese porphyrin superoxide dismutase (SOD) mimetic MnTBAP rescued the mice from the heart-and-liver disease and dramatically prolonged their survival (1998), but because MnTBAP does not cross the blood-brain barrier, the mice instead developed a movement disorder and spongiform brain degeneration by three weeks of age. Synthetic SOD-catalase mimetics (2001) extended lifespan threefold and rescued the spongiform brain disease. This pharmacologic rescue confirms that the lethal lesion is specifically loss of dismutase activity, not some other unrelated function of the SOD2 protein.
The heterozygous knockout (SOD2+/-, one functional copy) is viable and externally normal but shows increased mitochondrial DNA damage, accelerated cellular senescence in cultured fibroblasts, increased incidence of lymphoma with age, and reduced exercise capacity. This partial-deficiency phenotype is often compared with the human Val16Ala polymorphism discussed below; in laboratory import tests it is the Val16 form, not the Ala16 form, that yields less active enzyme inside mitochondria.
SOD2 Polymorphisms: Val16Ala (rs4880) and Disease Risk
The most-studied polymorphism in the SOD2 gene is a single-nucleotide difference at position 47 (T or C) that makes codon 16 in the mitochondrial targeting sequence either valine (T) or alanine (C) (Val16Ala, dbSNP rs4880). The polymorphism does not affect the enzyme's catalytic activity per se, but it affects how efficiently the newly translated MnSOD precursor protein is imported into mitochondria and processed into its mature form.
- Val form — computer models predict that the Val targeting sequence folds as a beta-sheet. In a 2003 study of import into rat liver mitochondria, the Val-MnSOD precursor was partly arrested within the inner mitochondrial membrane, and less of the active enzyme formed in the mitochondrial matrix.
- Ala form — the Ala targeting sequence is predicted to fold as a partial alpha-helix and allowed efficient import into the mitochondrial matrix; in the same study the Ala-MnSOD precursor generated 30–40% more of the active, processed MnSOD (the four-part homotetramer) than the Val precursor.
- Val/Ala heterozygotes — carry one copy of each form.
Population frequencies vary by ancestry: in European populations, Val and Ala alleles are roughly balanced (each about 50%); in East Asian populations, the Val allele is more common (about 85%); in African populations, the Ala allele predominates.
Epidemiologic studies of this variant have reported:
- Idiopathic cardiomyopathy — elevated risk of dilated cardiomyopathy and earlier onset of heart failure
- Doxorubicin cardiotoxicity — oncology patients with the Ala/Ala genotype have significantly higher risk of cardiotoxicity from anthracycline chemotherapy, which acts in part through mitochondrial superoxide generation
- Diabetic kidney disease — in a 2014 study of 1,285 people with type 1 diabetes, the T allele of rs4880 (the one that encodes valine) was linked to new or worsening kidney disease (hazard ratio 1.99 in the 10-year cohort) and a faster fall in kidney filtration (estimated glomerular filtration rate, eGFR); the risk allele also went with higher blood levels of an oxidative-stress marker and lower superoxide dismutase activity
- Cancer — individual studies gave inconsistent results; a 2008 meta-analysis of 13 case-control studies (7,366 cancer cases and 9,102 controls) found no overall association with breast cancer or with cancer risk in general (odds ratios for Ala homozygotes 0.98 and 1.02)
- Neurodegenerative disease — modest but consistent associations with Parkinson's disease and amyotrophic lateral sclerosis risk
- Longevity — Val/Val homozygotes have been reported as overrepresented in centenarian populations in some cohorts
Neither genotype is a disease in itself. The idea under study is that people whose MnSOD is imported less efficiently may be more vulnerable to insults that increase mitochondrial superoxide production (hyperglycemia, ischemia-reperfusion, prolonged inflammation). Genetic testing for rs4880 is widely available through consumer genomics platforms, and the Val/Ala status is one of the more actionable single-nucleotide variants for personalizing antioxidant strategy. Genetic testing for rs4880 is offered by consumer genomics services, but none of the studies cited on this page tested whether adjusting manganese or antioxidant intake by genotype changes health outcomes.
SIRT3 Regulation of MnSOD Activity (Acetylation Code)
One of the most important regulatory discoveries of the past decade has been that MnSOD activity is controlled post-translationally by acetylation, and the principal deacetylase is SIRT3 — the mitochondrial member of the sirtuin family of nicotinamide adenine dinucleotide-dependent deacetylases.
MnSOD carries acetyl groups on several lysines: a 2010 study identified lysine 122 as a site whose deacetylation by SIRT3 regulates activity, and a second 2010 study found that SIRT3 deacetylates two critical lysines on SOD2. Acetylation at these sites reduces enzymatic activity. SIRT3 removes the acetyl groups, restoring full activity. The result is that MnSOD function is dynamically linked to cellular nicotinamide adenine dinucleotide (NAD+) status:
- High nicotinamide adenine dinucleotide (fasting, caloric restriction, exercise) — SIRT3 is highly active, MnSOD is largely deacetylated and at maximum activity, mitochondrial antioxidant defense is upregulated
- Low nicotinamide adenine dinucleotide (overfeeding, sedentary lifestyle, aging) — SIRT3 activity falls, MnSOD becomes increasingly acetylated, antioxidant defense capacity drops at exactly the time when oxidative challenge is rising
This regulatory circuit ties MnSOD to the broader sirtuin-NAD+-mitohormesis network that underlies many of the documented benefits of caloric restriction, intermittent fasting, and aerobic exercise. The interventions that boost SIRT3 activity (caloric restriction, exercise, nicotinamide adenine dinucleotide precursor supplementation like nicotinamide riboside or nicotinamide mononucleotide) all converge on enhanced MnSOD function as one of their downstream effects.
The calorie-restriction link comes from animal work: in a 2010 mouse study, calorie restriction lowered oxidative stress and damage, and this protection was diminished in mice lacking SIRT3; SIRT3 lowered cellular reactive oxygen species in a way that depended on SOD2 and greatly increased SOD2's ability to protect cells against oxidative stress.
For the broader mitochondrial-antioxidant context, see our Oxidative Stress page and the discussion of mitohormesis interventions.
Oxidative Stress in Aging and the Mitochondrial Theory
The free radical theory of aging was proposed by Denham Harman in 1956; in 1972 he pointed to the mitochondria, and the mitochondrial free radical theory, refined over the following decades, holds that cumulative oxidative damage to mitochondrial DNA, proteins, and membranes is a primary driver of cellular aging. MnSOD is the central enzyme that determines how much of this damage accumulates over a lifetime.
Lines of evidence supporting MnSOD's role in aging:
- SOD2 expression declines with age in most tissues studied (heart, brain, kidney), and the decline is more pronounced in tissues that show greatest age-related dysfunction
- SIRT3 expression also declines with age, doubling the hit on MnSOD activity (less enzyme, and what enzyme remains is less active because of acetylation accumulation)
- SOD2 overexpression in flies and worms extends lifespan — in Drosophila, MnSOD overexpression switched on throughout the adult body raised mean lifespan by an average of 16%, with some lines showing 30–33% increases (2002)
- Mitochondrially targeted antioxidants extend lifespan — compounds aimed at mitochondria, such as mitoquinone and elamipretide (also called SS-31), extend healthspan in animal models, supporting the broader paradigm
- Elamipretide: approved for one rare disease, negative in a broader trial — elamipretide, a small peptide that binds cardiolipin in the inner mitochondrial membrane, received FDA accelerated approval in 2025 to improve muscle strength in people with Barth syndrome (a rare inherited mitochondrial disease) weighing at least 30 kg, based on improved knee-muscle strength; the label states that continued approval may depend on a confirmatory trial. In the 168-week open-label extension of its earlier trial, 8 patients reached week 168 with a cumulative 96.1-metre gain in 6-minute walk distance (this extension had no placebo group). In contrast, a 2023 phase-3 trial in 218 adults with primary mitochondrial myopathy found that elamipretide 40 mg a day under the skin did not improve walking distance or fatigue over 24 weeks compared with placebo.
- Centenarians show preserved MnSOD function — comparative studies of centenarians vs population norms have found higher MnSOD activity in centenarian fibroblasts and lymphocytes, even after accounting for genotype
- Mitochondrial heteroplasmy — mitochondrial DNA damage accumulates with age, and tissues with high MnSOD activity show slower accumulation
The hypothesis drawn from this work is that factors supporting MnSOD function (adequate manganese, SIRT3 activation, nicotinamide adenine dinucleotide adequacy, regular aerobic exercise, periodic caloric restriction) converge on the same mitochondrial defense system and could add together. None of these is a magic bullet individually, and none of the studies cited here tested that combination in people.
Disease Associations: Cancer, Neurodegeneration, Cardiomyopathy
Reduced MnSOD function (whether genetic, regulatory, or nutritional) has been linked to several major disease categories:
- Cancer — the MnSOD-cancer relationship is complex. In many cancers, MnSOD is paradoxically upregulated as the tumor adapts to its high metabolic and oxidative load, and high tumor MnSOD expression correlates with chemotherapy resistance and poor prognosis. In the surrounding stroma and normal tissues, however, low MnSOD activity is permissive for initial transformation. This has led researchers to propose a two-sided approach: raising MnSOD activity in normal tissues to prevent cancer, and inhibiting it in established tumors to make them more sensitive to treatment. Several MnSOD-targeting drugs are in development as cancer adjuvants.
- Cardiomyopathy and heart failure — the heart has among the highest mitochondrial density of any tissue, and MnSOD is essential for myocyte survival. SOD2 polymorphisms and acquired MnSOD deficiency are associated with cardiomyopathy, particularly idiopathic dilated cardiomyopathy and ischemia-reperfusion injury after myocardial infarction.
- Neurodegenerative disease — Parkinson's disease, amyotrophic lateral sclerosis, and Alzheimer's disease all show evidence of mitochondrial dysfunction and oxidative damage as core pathologic features. Reduced MnSOD activity is documented in affected brain regions in postmortem studies. Selective neuronal vulnerability (substantia nigra dopaminergic neurons in Parkinson's, motor neurons in amyotrophic lateral sclerosis (ALS)) may relate in part to differential MnSOD expression and capacity to handle endogenous oxidative stress.
- Diabetic complications — hyperglycemia accelerates mitochondrial superoxide production in vascular endothelium, retina, and renal tubular cells. The Brownlee unifying hypothesis of diabetic complications places this superoxide overproduction at the apex of the pathologic cascade leading to nephropathy, retinopathy, and neuropathy. Adequate MnSOD function would buffer this insult.
- Sepsis and critical illness — mitochondrial dysfunction is a central feature of severe sepsis. MnSOD activity is typically reduced in muscle biopsies from septic patients, contributing to the syndrome of "mitochondrial sepsis" and the weakness that follows an intensive care unit (ICU) stay.
Assessing MnSOD Activity and Manganese Status
Direct measurement of MnSOD activity is technically possible but not routinely available. Practical assessment of manganese-and-MnSOD status uses several proxies:
- Whole blood manganese — the most useful single test, reflecting longer-term tissue manganese status better than serum or plasma. Reference range approximately 4-15 µg/L. Available through major reference laboratories.
- Serum manganese — less reliable than whole blood because manganese is concentrated in cells. Useful for diagnosing toxicity but limited for deficiency assessment.
- Erythrocyte superoxide dismutase activity — can be measured directly from a blood draw. Reduced activity is suggestive of inadequate manganese (or copper/zinc for SOD1).
- Markers of oxidative damage — urinary 8-hydroxy-2-deoxyguanosine (8-OHdG, oxidative DNA damage marker), serum F2-isoprostanes (lipid peroxidation marker), and protein carbonyls all rise when MnSOD function is inadequate. These are sensitive but non-specific.
- SOD2 genotyping (rs4880) — available through consumer genomics services. The test reports which form of the targeting sequence a person carries; none of the studies cited here tested whether acting on the result changes health outcomes.
- Functional symptoms — while not specific, fatigue, exercise intolerance, slow recovery from physical or oxidative stress, and accelerated visible aging are loosely associated with chronic suboptimal mitochondrial function.
Practical Interventions: Diet, Lifestyle, Drug Considerations
- Dietary manganese — the US adult Adequate Intake is 1.8 mg/day for women and 2.3 mg/day for men, supplied by whole grains, nuts, legumes, leafy greens, and tea. Most varied diets supply this without difficulty. The Tolerable Upper Intake Level is 11 mg/day from all sources; excess manganese is toxic to the nervous system (see Manganese Toxicity).
- SIRT3 activity — the regulatory partner that determines how much MnSOD is active. Factors linked to higher SIRT3 activity in this research: regular aerobic exercise, intermittent caloric restriction or time-restricted eating, adequate nicotinamide adenine dinucleotide precursor intake (niacin, nicotinamide, or nicotinamide mononucleotide (NMN)/nicotinamide riboside (NR) supplementation), and less overfeeding (the calorie-restriction evidence comes from mice).
- Depleting factors — chronic alcohol abuse depletes mitochondrial nicotinamide adenine dinucleotide, reducing SIRT3 activity. Chronic high-dose iron supplementation can compete with manganese for the divalent metal transporter 1 (DMT1) and reduce manganese uptake. Sedentary lifestyle reduces mitochondrial biogenesis and MnSOD expression.
- Doxorubicin oncology patients — the SOD2 Val16Ala genotype meaningfully predicts cardiotoxicity risk.
- Diabetes — the mitochondrial-superoxide-overproduction model of diabetic complications places mitochondrial superoxide, and so MnSOD, at the centre of long-term complications; in this model, lower blood glucose reduces the substrate (superoxide) load on MnSOD.
- Neurodegenerative risk — Parkinson's, amyotrophic lateral sclerosis, and early-onset Alzheimer's all involve mitochondrial oxidative damage (see above). The evidence for any single intervention preventing these diseases is incomplete; the case for keeping mitochondrial defenses strong rests on mechanism.
- Athletes — chronic high-intensity training increases mitochondrial biogenesis and MnSOD expression as part of training adaptation. This is generally beneficial, but acute overtraining can transiently exceed antioxidant capacity. Recovery and dietary antioxidants are part of that adaptation, and excessive antioxidant supplementation has been reported to blunt training adaptation.
Safety fact: the Tolerable Upper Intake Level for adult manganese is 11 mg a day from food, water and supplements combined; excess manganese is toxic to the nervous system.
Key Research Papers
- Li Y et al. (1995). Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nature Genetics 11(4):376-381. — PubMed PMID: 7493016
- Lebovitz RM et al. (1996). Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. PNAS 93(18):9782-9787. — PubMed PMID: 8790408
- Sutton A et al. (2003). The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 13(3):145-157. — PubMed PMID: 12618592
- Qiu X et al. (2010). Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metabolism 12(6):662-667. — PubMed PMID: 21109198
- Tao R et al. (2010). Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Molecular Cell 40(6):893-904. — PubMed PMID: 21172655
- Bresciani G et al. (2015). Manganese superoxide dismutase and oxidative stress modulation. Advances in Clinical Chemistry 68:87-130. — PubMed PMID: 25858870
- Bag A, Bag N (2008). Target sequence polymorphism of human manganese superoxide dismutase gene and its association with cancer risk: a review. Cancer Epidemiol Biomarkers Prev 17(12):3298-3305. — PubMed PMID: 19064542
- Wang Y et al. (2018). Superoxide dismutases: dual roles in controlling ROS damage and regulating ROS signaling. Journal of Cell Biology 217(6):1915-1928. — PubMed PMID: 29669742
- Harman D (1956). Aging: a theory based on free radical and radiation chemistry. Journal of Gerontology 11(3):298-300. (Original free radical theory of aging.) — PubMed PMID: 13332224
- Mohammedi K et al. (2014). Manganese superoxide dismutase (SOD2) polymorphisms, plasma advanced oxidation protein products (AOPP) concentration and risk of kidney complications in subjects with type 1 diabetes. PLoS One 9(5):e96916. — PubMed PMID: 24819633
- Harman D (1972). The biologic clock: the mitochondria? Journal of the American Geriatrics Society 20(4):145-147. (Mitochondrial version of the free radical theory of aging.) — PubMed PMID: 5016631
- Elchuri S et al. (2005). CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene 24(3):367-380. — PubMed PMID: 15531919
- Melov S et al. (1998). A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase. Nature Genetics 18(2):159-163. — PubMed PMID: 9462746
- Melov S et al. (2001). Lifespan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics. Journal of Neuroscience 21(21):8348-8353. — PubMed PMID: 11606622
- Sun J et al. (2002). Induced overexpression of mitochondrial Mn-superoxide dismutase extends the life span of adult Drosophila melanogaster. Genetics 161(2):661-672. — PubMed PMID: 12072463
- Hearn AS et al. (2001). Kinetic analysis of product inhibition in human manganese superoxide dismutase. Biochemistry 40(40):12051-12058. — PubMed PMID: 11580280
- Thompson WR et al. (2024). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in Medicine 26(7):101138. — PubMed PMID: 38602181
- Karaa A et al. (2023). Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology 101(3):e238-e252. — PubMed PMID: 37268435
- U.S. National Library of Medicine, DailyMed (2025). Elamipretide injection, for subcutaneous use: prescribing information (indication under accelerated approval for Barth syndrome). — DailyMed label
PubMed Topic Searches
Connections
- All Minerals
- Manganese Overview
- Manganese Benefits Hub
- Manganese for Bone Formation
- Manganese for Wound Healing
- Manganese for Blood Sugar
- Oxidative Stress
- Zinc (CuZnSOD Partner)
- Copper (CuZnSOD Partner)
- Selenium (Glutathione Peroxidase Cofactor)
- Vitamin E
- Vitamin C
- Coenzyme Q10
- Parkinson's Disease
- Cardiomyopathy
- Oncology (Cancer)
- Type 2 Diabetes
- Copper-Iron Dysregulation
- Deficiency
- Toxicity
- History
- Sources